Abstract
Pheochromocytoma is a rare neuroendocrine tumour. The prognosis after metastasis is poor, but there have been rare cases of prolonged survival of up to 26 years. Treatments for malignant phaeochromocytoma include surgical debulking, pharmacological control of hormone-mediated symptoms, 131I-metaiodobenzylguanidine (MIBG) therapy, chemotherapy and hormone therapy such as somatostatin analogues. We report the case of a patient, treated only with 131IMIBG therapy, who has survived 28 years since her diagnosis in 1981. The primary lesion was removed in 1982 by adrenectomy. In 1987, urinary catecholamines began to rise, heralding the onset of multiple bone and lung metastases. Her only treatment has been six doses of 131I-MIBG therapy between 1988 and 2003, (total of 22,804MBq). These treatments have relieved pain and led to the resolution of some of the metastatic lesions. She is now 81 years old and is currently very well and asymptomatic, despite evidence of residual thoracic and lumbar vertebral metastases.
Current Radiopharmaceuticals
Title: Twenty-Eight Years Survival with Metastatic Phaeochromocytoma Treated by Repeated [131I] Metaiodobenzylguanidine Therapy
Volume: 3 Issue: 1
Author(s): M. R. S. Brothwell and H. H. Lucraft
Affiliation:
Abstract: Pheochromocytoma is a rare neuroendocrine tumour. The prognosis after metastasis is poor, but there have been rare cases of prolonged survival of up to 26 years. Treatments for malignant phaeochromocytoma include surgical debulking, pharmacological control of hormone-mediated symptoms, 131I-metaiodobenzylguanidine (MIBG) therapy, chemotherapy and hormone therapy such as somatostatin analogues. We report the case of a patient, treated only with 131IMIBG therapy, who has survived 28 years since her diagnosis in 1981. The primary lesion was removed in 1982 by adrenectomy. In 1987, urinary catecholamines began to rise, heralding the onset of multiple bone and lung metastases. Her only treatment has been six doses of 131I-MIBG therapy between 1988 and 2003, (total of 22,804MBq). These treatments have relieved pain and led to the resolution of some of the metastatic lesions. She is now 81 years old and is currently very well and asymptomatic, despite evidence of residual thoracic and lumbar vertebral metastases.
Export Options
About this article
Cite this article as:
R. S. Brothwell M. and Lucraft H. H., Twenty-Eight Years Survival with Metastatic Phaeochromocytoma Treated by Repeated [131I] Metaiodobenzylguanidine Therapy, Current Radiopharmaceuticals 2010; 3 (1) . https://dx.doi.org/10.2174/1874471011003010025
DOI https://dx.doi.org/10.2174/1874471011003010025 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets Pictorial US, CT and MRI Findings of Common Hepatic Tumours
Current Medical Imaging Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Current Cancer Drug Targets Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
Current Topics in Medicinal Chemistry Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Comparison of Artemisia annua Bioactivities between Traditional Medicine and Chemical Extracts
Current Bioactive Compounds Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Ethnomedicinal Uses, Phytochemistry and Pharmacology of Carica papaya Plant: A Compendious Review
Mini-Reviews in Organic Chemistry A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry